World Conference on Interventional Radiology (WCIO) and Best of ASCO 2008
June 22 - 25, 2008  |  Hyatt Regency Century Plaza  |  Los Angeles, CA
 
Home
Program
      CME Information
      WCIO Posters
Registration
Housing
LA Tours & Attractions
Exhibitors & Sponsors
Committees
Contact Us
Archives
      Washington DC
      Italy
      London
 
Search WCIO

powered by Search Powered by Google
 
Full Scientific Program

WCIO 2008 and Best of ASCO®
June 22 - 25, 2008
Hyatt Regency Century Plaza
Los Angeles, CA, USA

2008 Schedule-at-a-Glance ( 210kb)

View Best of ASCO® Sessions
 
SUNDAY, June 22, 2008
7:45 am – 8:00 am   Welcome Address
8:00 am - 10:00 am   Multimodality Session I:
Co-Chairs: Mike Choti, Jordan Berlin, Daniel Brown, Luigi Solbiati

COLORECTAL LIVER METASTASES
(15 min. presentations)
1. Systemic Chemotherapy in Colorectal Cancer: Advances and Integration with Locoregional Therapy
Jordan Berlin
2. Expanding the Role of Liver Resection in the Management of Liver Metastases
Michael Choti
3. Intraoperative Ablation: Indications and Results
Sandra Wong
4. Percutaneous Ablation of Liver Metastases
Luigi Solbiati
5. Transarterial Chemoembolization for Hepatic Colorectal Metastases
Thierry Debaere
6. Transarterial Radioembolization for Colorectal Metastases
Riad Salem
7. Selected ASCO/WCIO Abstracts
(5 Minute Presentations with 10 minute discussion at the end of the abstracts)

A1. (67) Transarterial Chemoembolization (TACE of liver metastases (LM) from colorectal carcinoma (CRC) adopting Drug Eluting Beads Preloaded with Irinotecan: Report of 62 Patients
C. Aliberti1, G. Benea1, M. Tilli1, G. Fiorentini2 - 1Delta Hospital Ferrara, Ferrara, Italy, 2General Hospital Empoli, Empoli, Italy.

A2. A Phase III Study Comparing TACE-DC Beads IRI Loaded (DEBIRI) with FOLFIRI Chemotherapy (CT) for Patients with Nonresectable Colorectal Cancer (CRC) Liver Metastases (LM)
C. Aliberti1, G. Benea1, R. Rizzati1, R. Righi1, M. Tilli1, I. Marri1, G. Fiorentini2 - 1Delta Hospital Ferrara, Ferrara, Italy, 2Empoli General Hospital, Empoli, Italy.

A3. A Phase II Clincial Trial on Hepatic Intra-arterial Injection of Yttrium-90 Microspheres in Unresectable Heavily Pre-treated Colorectal Liver Metastases
L. Carpanese1, G. Pizzi1, R. Golfieri2, F. Fiore3, D. Gasparini4, C. L. Maini1, R. Sciuto1, M. Cosimelli1 - 1IFO Istituto Regina Elena National Cancer Institute, Roma, Italy, 2Ospedale S.Orsola Malpighi, Bologna, Italy, 3Fondazione G. Pascale" National Cancer Institute

Discussion (10 minutes)
10:00 am - 10:30 am   Coffee Break
(Exhibit Hall)
10:30 am - 11:45 am   Multimodality Session II:
Co-Chairs: Yuman Fong, Mike Wallace & Alice Gillams

NON-COLORECTAL LIVER METASTASES
(15 min. presentations)
1. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Medical Management And Rationale for Loco-Regional Therapy
Al Benson
2. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Surgical Management
Yuman Fong
3. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Transarterial Therapy
Michael Wallace
4. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Ablative Therapy
Alice Gillams
5. Selected ASCO/WCIO Abstract
(5 Minute Presentation with 5 minute discussion at the end of the abstracts)

A4. Treatment of Intrahepatic Cholangiocarcinoma Using Y90 Radioactive Microspheres: A Single Institutional Experience
S. M. Ibrahim, M. F. Mulcahy, R. J. Lewandowski, K. T. Sato, A. Benson III, R. Salem; Northwestern University, Chicago, IL.

Discussion (5 Min.)
11:45 am - 12:30 pm   Multimodality Session III: LIVER METASTASES TUMOR BOARD
Co-Chairs: Bill Lees, Al Benson, Yuman Fong
12:30 pm - 1:30 pm   Lunch Break & Poster Viewing
1:30 pm - 3:30 pm   Basic Science and Technology Session I:
Co-Chairs: Stephen Solomon & Fred Lee

ADVANCES IN ENERGY BASED AND EMBOLIC THERAPIES
(10 min. presentations)

Tissue Ablation:
1. Basic Science and Advances in Thermal Ablation
Chris Brace
2. Basic Science and Advances in Cryotherapy
Peter Littrup
3. Basic Science and Advances in HIFU
Fiona Fennessy
4. Basic Science and Advances in Irreversible Electroporation
Boris Rubinsky
5. Stereotactic radiosurgery/IMR/IGRT
Thomas Mackie


Trans-arterial Therapy:
6. Biology and Advances in Drug Eluting Beads
Peter Stratford
7. Radio-Embolization: Foundation and Future
Andrew Kennedy
8. New Intra-Arterial Chemotherapeutics
Jeff Geschwind
9. Oncolytic Viruses and Novel Agents
Anthony Reid
10. Selected ASCO/WCIO Abstract
(5 Minute Presentations with 10 minute discussion at the end of the abstracts)

A5. Microwave Ablation: Multiple-antennas Spatially Distribute Power and Significantly Improve Thermal Profiles While Potentially Reducing Invasiveness
P. F. Laeseke, D. W. van der Weide, F. T. Lee, Jr, C. L. Brace; University of Wisconsin, Madison, WI.

A6. Low-frequency RF Ablation: Ex-vivo Studies to Demonstrate Preferential Heating of Tumors
D. J. Schutt1, S. Shah2, P. Guion2, B. J. Wood2, D. Haemmerich1; 1Medical University of South Carolina, Charleston, SC, 2NIH, Bethesda, MD.

A7. Tumor Ablation with a Hybrid Cryotherapy and Radiofrequency System using a Gas-Cooled Probe - Results of an Ex-vivo Application Study
H. Rempp1, M. Voigtländer2, S. Kempf1, A. Neugebauer2, S. Clasen1, C. Schraml1, C. D. Claussen1, M. D. Enderle2, N. S. Goldberg3, P. L. Pereira1; 1University of Tübingen, Tübingen, GERMANY, 2ERBE Elektromedizin, Tübingen, GERMANY, 3Beth Israel Deaconess Medical Center, Boston, MA.

A8. Microbubble Platform for Non-invasive US-mediated Drug Delivery to Liver Tumors: In-vivo Evaluation
J. Eisenbrey1, M. A. Wheatley1, M. C. Soulen2; 1Drexel University, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA.

A9. Preliminary Study of Ultrasound Image-guided High Intensity Focused Ultrasound (HIFU) Treatment for Solid Tumors in an European Comprehensive Cancer Center
F. Orsi1, P. Arnone1, L. Zhang2, P. Della Vigna1, L. Monfardini1, G. Bonomo1, K. Zhou2, W. Chen2, Z. Wang2; 1European Institute of Oncology, Milan, Italy, 2Clinical Center for Tumor Therapy of 2nd Hospital of Chongqing University of Medical Sciences, Chongqing, China.

Discussion (10 Min.)
1:30 pm - 3:30 pm   Concurrent ONCOLOGY SESSION I: BEST OF ASCO

1.  Welcome and Introductions - Mark Pegram, Masakatsu Toi
 
2.  Gastrointestinal Colorectal Cancers - Al Benson
Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301)

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials.
 
3.  Gastrointestinal Non-Colorectal Cancers - Jordan Berlin
CONKO-001: Final Results of the randomized, prospective, multicenter phase 3 trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer (PC)

A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907)

A randomized, double blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma

A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201
 
4.  Genitourinary Cancers - William Figg
RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC), which has progressed on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-3 study

Radiotherapy versus Carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomised trial (ISRCTN27163214)

Abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, has significant and durable anti-tumor activity in both chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)

Impact of Androgen Deprivation Therapy (ADT) on bone, cardiovascular, and endocrine outcomes: a propensity-matched analysis of 20,000 patients
 
3:30 pm - 4:00 pm   Refreshment Break
(Exhibit Hall)
4:00 pm - 5:30 pm   IO TREATMENT STRATEGIES Session I: LIVER METASTASES
Co-Chairs: Riad Salem & Fred Lee

Percutaneous ablation of liver metastases:
(10 min. presentations)
1. Patient Selection and Anatomic Considerations
Fred Lee
2. Optimizing RFA Technique
Alice Gillams
3. Ct/Us In Ablation Guidance and Monitoring
Louis Hinshaw
4. Post Ablation Imaging and Management
Philippe Pereira


Transcatheter therapy of liver metastases:
(7 min. presentations)
1. Portal Vein Embolization
David Madoff
2. Bland Embolization
Karen Brown
3. Chemoembolization
Daniel Sze
4. Radioembolization
Jose Bilbao
5. Chemo-infusion
Yasuaki Arai
6. Debate on Trans-arterial Techniques
4:00 pm - 5:30 pm   Concurrent ONCOLOGY SESSION II: BEST OF ASCO

1.  Breast Cancer - Local Regional Adjuvant Therapy – Peter Ravdin
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older. Results of CALGB/CTSU 49907

Vitamin D (Vit D) deficiency is common at breast cancer (BC) diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC

tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC)

Zoledronic Acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809
 
2.  Breast Cancer - Metastatic - Mark Pegram
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer

Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue microarray series
 
3.  Melanoma - Donald Morton
Final results of the Sunbelt Melanoma Trial

Sentinel lymph node biopsy (SLNB) improves survival among SEER patients with melanoma
 
6:00 pm - 7:30 pm   Welcome Reception
7:30 pm - 9:30 pm   AngioDynamics Symposium - Novel Thermal and Non-Thermal Ablation Techniques in the Management of Malignancies
 
MONDAY, June 23, 2008
7:00 am - 8:00 am   Ablation Workshop
8:00 am - 10:00 am   Multimodality Session IV: LUNG MALIGNANCIES
Co-Chairs: Steven Rose, Thomas DePetrillo, Hiran Fernando, Lyudmila Bazhenova

NON-SMALL CELL LUNG CANCER
(15 min. presentations)
1. NSCLC: Overview of Staging and Medical Therapy
Lyudmila Bazhenova
2. NSCLC: Surgical Resection, Indication and Results
Hiran Fernando
3. NSCLC: Percutaneous RFA: Indication and Results
Steven Rose
4. NSCLC: Alternative Ablative Therapies
Damian Dupuy
5. NSCLC: Radiation Therapy with/without Ablation: Indications and Results
Tom Dipetrillo
6. Selected ASCO/WCIO Abstract
(5 Minute Presentation with 2 minute discussion at the end of the abstract)

A10. RFA Following EBRT Improves Survival of NSCLC in Bangladesh
A. S. Murshed - American SuperSpecialty Hospital Ltd, Dhaka, Bangladesh.

Discussion (2 Min.)


LUNG METASTASES
(15 min. presentations)
7. Lung Metastases: Role of Surgical Resection
Garrett Walsh
8. Lung Metastases: Role of Ablative Therapy
Koichiro Yamakado
9. Selected ASCO/WCIO Abstract
(5 Minute Presentation with 2 minute discussion at the end of the abstract)

A11. Clinicial Study on Targeted Argon-Helium Cryotherapy in Treatment for 725 Cases with Pulmonary Neoplasms
H. S. Feng; Navy General Hospital, Beijing, China.

Discussion (2 Min.)
10:00 am - 10:30 am   Coffee Break
(Exhibit Hall)
10:30 am - 11:00 am   Multimodality Session V: LUNG TUMOR BOARD
Co-chairs: Damian Dupuy, Roberto Orrechia, Garrett Walsh
11:00 am - 12:00 pm   Multimodality Session VI: BONE METASTASES AND PAIN PALLIATION
Co-Chairs: Matthew Callstrom & Nora Janjan
(10 min. presentations)

1. Medical and Surgical Management and Rationale for Loco-regional Therapies
Thomas Smith
2. Radiation Therapy of Painful Bone Metastases
Nora JanJan
3. RFA of Painful Bone Metastasis
Damian Dupuy
4. Cryoablation and Stabilization of Painful Bone Metastases
Matthew Callstrom
5. Ablation and Stabilization of Vertebral Body Tumors
Afsin Gangi
6. Selected ASCO/WCIO Abstract and/or Q&A
(5 Min. Presentations followed by 5 min. discussion)

A12. Percutaneous Cryotherapy of Soft Tissue (Non-organ) Metastases: Potential for Local Control with Low Morbidity as a Flex Adjunct to Systemic Therapy
P. J. Littrup1, H. D. Aoun2, D. Cyriac2, B. A. Adam1 - 1Karmanos Cancer Center, Detroit, MI, 2Wayne State University, Detroit, MI.

Discussion (2 min.)
12:00 pm - 12:30 pm   Keynote Speaker
Molecular Diagnostics: Key to Molecular Therapies
Michael Phelps, UCLA Molecular & Medical Pharmacology
12:30 pm - 1:30 pm   Lunch Break & Poster Viewing
(Exhibit Hall)
1:30 pm - 3:30 pm   Basic Science and Technology Session II:
ADVANCES IN IMAGE GUIDANCE AND MONITORING

Co-Chairs: Philippe Pereira, Luigi Solbiati, Bradford Wood
(15 min. presentations)

1. Advances in Interventional US (Contrast Agents, Real-time Fusion Imaging)
Luigi Solbiati
2. Advances in 3D Fluoroscopy
Marshall Hicks
3. Advances in Interventional CT
Thomas Helmberger
4. Advances in Interventional MRI (guidance, monitoring, assessment)
Philippe Pereira
5. Newest Technological Advancements (Multimodality Imaging, Robotics)
Bradford Wood
6. Role of Molecular Imaging in Image Guided Intervention
Johannes Czernin
7. Selected Abstracts
(5 Minute Presentations with 10 minute discussion at the end of the abstracts)

A13. CT-fluoroscopic Imaging of Ablation Zone Growth: Improved Visualization with Periodic Contrast Injections and HYPR Reconstruction
C. L. Brace, C. A. Mistretta, P. F. Laeseke, L. A. Sampson, J. Hinshaw, F. T. Lee, Jr - University of Wisconsin, Madison, WI.

A14. Relationships Between Ablative Margin and Local Tumor Progression After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: Three-dimensional Quantitative Analysis Using CT Image Fusion and Multi-planar Reformatting
Y. Kim, W. Lee, H. K. Lim, H. Rhim, D. Choi; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

A15. High-Intensity Ultrasound Ablation of the Canine Prostate: Monitoring and Post-Procedural Assessment with Magnetic Resonance Imaging
V. Rieke1, J. Chen1, A. B. Holbrook1, D. M. Bouley1, C. J. Diederich2, G. Sommer1, K. Butts Pauly1; 1Stanford University, Stanford, CA, 2UCSF, San Francisco, CA.

Discussion (10 min.)
1:30 PM - 3:30 PM   Concurrent ONCOLOGY SESSION III: BEST OF ASCO

1.  Lung Cancer - David Gandara
S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)

Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial

Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): Interim results

Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary end-point analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212)

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC)

A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients

Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
 
2.  Patient and Survivor Care - Patricia Ganz
A Phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP Study

Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer

Cardiovascular disease in adult survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study (CCSS)

Management recommendations for women at increased familial risk for breast cancer: Results of a prospective national multi-modality cohort study
 
3.  Gynecologic Cancers - Maurie Markman
Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology

AZD2281 (KU-0059436), a PARP (Poly ADP-ribose Polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a Phase I study
 
3:30 pm - 4:00 pm   Refreshment Break
(Exhibit Hall)
4:00 pm - 5:30 pm   IO TREATMENT STRATEGIES Session II:
LUNG AND METASTATIC BONE TUMORS


Lung Tumors:
Co-Chairs: Robert Suh, Steven Rose
(15 min. presentations)

1. Patient Selection and Evaluation
Karin Steinke
2. Optimizing Ablative Technique
Damian Dupuy
3. Clinical and Imaging Follow-up
Robert Suh
4. Complications and Management
Kamran Ahrar


Bone and Soft Tissue Tumors
(15 min. presentations)
Chair: William Charboneau
5. Vertebral Body
Afshin Gangi
6. Bone
William Charboneau
4:00 pm - 5:30 pm   Concurrent ONCOLOGY SESSION IV: BEST OF ASCO

1.  Lymphoma/Leukemia/Myeloma – Michael Lill & Robert Vescio
Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups

International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma

A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)

Azacitidine (AZA) extends overall survival in higher-risk myelodysplastic syndromes (MDS) without necessity for complete remission

Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)

Total therapy (TT) for myeloma (MM): 10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2

Bortezomib/Dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial
 
2.  Developmental Therapeutics - TBD
A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors

A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors
 
6:00 pm - 8:00 pm   Industry Symposium
Multidisciplinary Management of Hepatocellular Carcinoma
Sponsored by Educational Concepts Group and supported by an educational grant from Bayer Healthcare and Onyx Pharmaceuticals
 
TUESDAY, June 24, 2008
7:00 am - 8:00 am   Image Guidance Workshop
8:00 am - 10:00 am   Multimodality Session VII:
HEPATOCELLULAR CARCINOMA

Co-Chairs: Riccardo Lencioni, Ronald Busuttil, Jeff Geschwind, Myron Tong
(10 min. presentations)

1. Clinical Overview and Natural History
Myron Tong
2. Surgical Resection: Patient Selection and Outcomes
Nicolas Vauthey
3. Transplantation: Patient Selection and Outcomes
Ronald Busuttil
4. TAE/TACE: Indications and Outcomes
William Rilling
5. TACE with Drug Eluting Beads
Jeff Geschwind
6. Radioembolization: Indications and Outcomes
Riad Salem
7. Percutaneous Chemical Ablation: Indications and Outcomes
Michael Soulen
8. Percutaneous Thermal Ablation: Indications and Outcomes
Gerald Dodd
9. Role of Loco-regional Therapies as Bridge to Transplant
David Lu
10. Combining Transarterial and Ablative Therapies
Riccardo Lencioni
11. Integrating HCC Management with Loco-regional and Advances in Systemic Therapies
TBD
12. Q & A
10:00 am - 10:30 am   Coffee Break
(Exhibit Hall)
10:30 am - 11:00 am   Multimodality Session VIII:
HEPATOCELLULAR CARCINOMA (CONTINUED)


13. Selected ASCO/WCIO Abstracts
(5 Minute Presentations with 10 minute discussion at the end of the abstracts)

A16. TACE Sequentially Combined with RFA and CIKS infusion for HCC
P. Wu, J. Xia, M. Zhao, Q. Zhou, Q. Wang, L. Huang, Y. Li, S. Chen - Sun Yat-sen University, Guangzhou, China.

A17. Percutaneous Thermal Ablation Treatment for Medium and Large Hepatocellular Carcinoma: Long-term Outcome and Prognostic Factors
M. Kuang, X. Yin, X. Xie, M. Lu - The first Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

A18. Does Neoadjuvant Therapy for HCC Decrease Dropout Rates Among Patients Listed for OLT?
M. Vella, K. Olthoff, A. Shaked, R. Reddy, M. Rosen, M. C. Soulen - University of Pennsylvania, Philadelphia, PA.

Discussion (10 Min.)
11:00 am - 12:00 pm   Multimodality Session IX:
HCC INTERNATIONAL TUMOR BOARD

Co-Chairs: Riccardo Lencioni, Jordan Berlin, Marisato Sato, Nicolas Vauthey
12:00 pm - 12:30 pm   Keynote Lecture
Image Guided Therapy in the Genomic Era
King C. Li, MD, The Methodist Hospital, Department of Radiology
12:30 pm - 1:30 pm   Lunch Break & Poster Viewing
(Exhibit Hall)
1:30 pm - 3:30 pm   IO TREATMENT STRATEGIES Session III:
TRANSARTERIAL THERAPY FOR HCC

Co-Chairs: William Rilling, Yasuaki Arai, Ren-jie Yang
(15 min. presentations)

1. Clinical Evaluation and Patient Selection in Transarterial Therapies for HCC
William Rilling
2. HCC Treatment Planning and Endpoint Determination with CTA and CTAP
Yasuaki Arai
3. TACE for HCC: Optimizing Technique
Jae-Hyung Park
4. TACE and Interventional Management in Advanced, Complicated HCC
Ren-jie Yang
5. Y 90 Radioembolization for HCC: Optimizing Technique
Jose Bilbao
6. Complications and Management of Transarterial Therapies
Daniel Brown
7. Post Therapy Imaging and Follow Up:
a. Post TAE/TACE and Radioembolization
Robert Lewandowsky
8. Selected Abstracts
(5 Minute Presentations with 5 minute discussion at the end of the abstracts)

A19. Actual Survival Following Chemoembolization for Hepatocellular Carcinoma in a U.S. Center: Correlation with Prognostic Systems
A. Weiss1, M. C. Soulen2, S. W. Stavropoulos2, J. I. Mondschein2, A. A. Patel2 - 1University of Pennsylvania, Philadlephia, PA, 2University of Pennsylvania, Philadelphia, PA.

A20. The Significance of Alpha-Fetoprotein Reduction After Y90 Radioembolization for Unresectable Hepatocellular Carcinoma: A Subgroup Comparison of Producers Versus Nonproducers
R. K. Ryu, S. Ibrahim, R. J. Lewandowski, R. A. Omary, K. T. Sato, R. Salem - Northwestern University, Chicago, IL.

Discussion (5 Min.)
1:30 pm - 3:30 pm   Concurrent ONCOLOGY SESSION V:
TISSUE GENE/MOLECULAR PROFILING & TARGETTED THERAPIES

Co-Chairs: Mark Pegram, Gary Dorfman, James Economou

1. Introduction an Oncologic Overview
Mark Pegram
2. What is the Opportunity, What Are the Barriers
Gary S. Dorfman
3. Advances in Biopsy Techniques
Brad J. Wood
4. Advances in Biospecimen Analysis and Its Role in Guiding Targeted Therapies
Richard J. Cote
5. Linking In Vitro and In Vivo Data: Imaging Phenotypes
Michael Kuo
6. Panel Discussion, Q & A
3:00 pm - 4:00 pm   Refreshment Break
(Exhibit Hall)
4:00 pm - 5:30 pm   IO TREATMENT STRATEGIES Session IV:
ABLATIVE THERAPY FOR HCC

Co-Chairs: Gerald Dodd & Hyo Keun Lim
(10 min. presentations)

1. Imaging Criteria and Biopsy in Diagnosis of HCC
Steve Raman
2. Alcohol Ablation - Optimizing technique
Chia Sing Ho
3. Thermal Ablation - Optimizing Technique
Hyuncul Rhim
4. Advanced Ablation Strategies in Difficult Cases
David Lu
5. Complications and Management of Percutaneous Ablations
Gerald Dodd
6. Post RFA Imaging
Hyo Keun Lim
7. Selected Abstracts and/or Q&A
(5 Minute Presentations with 10 minute discussion at the end of the abstracts)

A21. Treatment of Malignant Liver Tumors with Percutaneous Microwave Ablation: Experience with Complications in 1136 Patients
P. Liang, Y. Wang, X. Yu, Y. Gao, H. Ren - Department of Ultrasound, PLA general hospital, Bejing, China.

A22. Treatment Strategy and Efficacy of Radiofrequency Ablation in 172 Patients with 3.5 Hepatocellular Carcinoma
W. Yang, M. Chen, W. Wu, Y. Fu, J. Wu, Y. Hou, K. Yan - The School of Oncology, Peking University, Beijing, China.

A23. Percutaneous Ethanol Injection of Hepatocellular Carcinoma with Single Treatment Session by Using a Multi-pronged Injection Needle
X. XIE, M. KUANG, M. LU - The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China, Guangzhou, China.

Discussion (10 Min.)
4:00 pm - 5:30 pm   Concurrent ONCOLOGY SESSION VI:
Co-Chairs: Gary Dorfman & Mark Pegram

1. Additional ASCO highlights
2. Clinical Trials Update
5:30 pm - 6:30 pm   Focus Session: Bridge to China 2009
Co-Chairs: Ren Jie Yang, David Lu
(7 min. presentations)

1. New advances of microwave ablation in China
Ping Liang
2. RFA vs surgery in the treatment of small HCC
Ming Shan Chen
3. Role of RFA in the treatment of large HCC
Ming Hua Chen
4. Ethanol ablation of HCC with multi-pronged injection
Xiao Yan Xie
5. TACE in prevention and treatment of postoperative recurrence of HCC
Sheng Long Ye
6. TAE with iodized oil and pingyangmycin for hemangiomas of liver
Ke Xu
7. Percutaneous cryoablation of non small cell lung cancer
Ji Ren Zhang
 
WEDNESDAY, June 25, 2008
7:00 am - 8:00 am   Transarterial Therapy Workshop
8:00 am - 10:00 am   Multimodality Session X:
GENITOURINARY MALIGNANCIES

Co-Chairs: Debra Gervais, Surena Matin, Peter Mueller

Renal Cell Carcinoma and Renal Masses
(10 min. presentations)
1. Clinical Overview and Natural History
Robert Figlin
2. Systemic Therapy
Robert Figlin
3. Surgical Resection
Surena Matin
4. RFA for RCC
David Breen
5. Cryoablation for RCC
William Charboneau
6. Transcatheter Embolization of Renal Masses
Kamran Ahrar


IO in Other GU Malignancies
(10 min. presentations)
7. Percutaneous Adrenal Ablation
William Mayo-Smith
8. Regional Radiation Therapy for Prostate Cancer
Thomas DiPetrillo
9. Focal Ablative Therapy for Prostate Cancer
Gary Onik
10. Role of Ablation in Ovarian Cancer
Debra Gervais
11. Selected ASCO/WCIO Abstract and/or Q&A
(5 Minute Presentations with 5 minute discussion at the end of the abstracts)

A24. Laparoscopic RFA for Small Renal Masses: Initial Clinical Series
S. Williams, R. Leveillee, M. Wingo, V. Bird - University of Miami, Miami, FL.

A25. Percutaneous Cryotherapy of Renal Cell Carcinoma (RCC): Low Complication and Recurrence Rates Beyond 12 Months
P. J. Littrup1, H. D. Aoun2, B. A. Adam1 - 1Karmanos Cancer Center, Detroit, MI, 2Wayne State University, Detroit, MI.

A26. Nephron-sparing Radiofrequency Ablation of Renal Cell Carcinoma in Patients with a History of Contra-Lateral Nephrectomy: Initial Clincial Experience
W. Prevoo, M. A. van den Bosch, F. van Coevorden, S. Horenblas - The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Discussion (5 Min.)
10:00 am - 10:30 am   Coffee Break
(Exhibit Hall)
10:30 am - 11:00 am   Multimodality Session XI:
GENITOURINARY TUMOR BOARD

Co-Chairs: Kamran Ahrar & Surena Matin
11:00 am - 12:30 pm   MULTIMODALITY SESSION XII:
EXPLORING SYNERGIES: SYSTEMIC, LOCAL/REGIONAL, ENERGY, DRUGS, AND BIOLOGIC AGENTS

Co-Chairs: S. Nahum Goldberg, Thomas DiPetrillo, Keith Stuart, Michael Soulen
(10 min. presentations)

1. Enhancing Anti-tumoral Efficacy by Transarterial Delivery
Michael Soulen
2. Targetted Energy Activation and Systemic Agents
S. Nahum Goldberg
3. Antiangiogenesis and Minimal Invasive Therapy
Robert Figlin
4. Thermal Ablation and Radiation Therapy
Tom DiPetrillo
5. Immunologic Modulation and Interventional Oncology
Elizabeth Repasky
6. The Case for Adding Focal Therapy to Medical Oncology Practice
Keith Stuart
7. Selected abstracts and/or Q&A
(5 Minute Presentations with 10 minute discussion at the end of the abstracts)

A27. Phase I Dose Escalation Study of Thermally Sensitive Lipsomal Doxorubicin (Thermodox) in Combination with Radiofrequency Ablation (RFA) of Primary and Metastastic Tumors to the Liver: Interim Report
T. S. Ravikumar1, K. Fehn1, R. Prabhakar2, N. Borys2, C. Black2 - 1NS-LIJ Health System, New Hyde Park, NY, 2Celsion Corporation, Columbia, MD.

A28. A Phase II Study of Selective Internal Radiation Treatment (SIRT) and Selective External Radiation Treatment (SERT) with Chemotherapy in Patients with Recurrent/Metastatic Pancreatic Cancer
M. J. Hall, K. Pennington, S. Gulec - Goshen General Hospital, Goshen, IN.

A29. Direct Intratumoral Therapy of Human Squamous Cell Carcinoma in a Rat Model: Comparison of Efficacy of Combinations of Doxil, Liposome Encapsulated 186Re. and Radiofrequency Ablation
X. Garcia-Rojas, A. Bao, W. T. Phillips, A. Soundararajan, B. Goins, G. D. Dodd III - University of Texas Health Science Center at San Antonio, San Antonio, TX

A30. A Pilot Study of Intravenous Bevacizumab in Hepatocellular Cancer Patients Undergoing Chemoembolization
C. D. Britten1, A. Gomes1, N. Bucher1, R. Amado1, L. Yonemoto1, G. Bentley1, R. Mass2, R. W. Busuttil1, D. J. Slamon1, R. S. Finn1 - 1David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Genentech, South San Francisco, CA.

Discussion (10 Min.)
12:30 pm - 1:30 pm   Lunch And Poster Viewing
(Exhibit Hall)
1:30 pm - 2:30 pm   Multimodality Session XIII:
Emerging IO Applications

Co-Chairs: John McGahan & Ross Abrams
(10 min. presentations)

1. Chemo-embolization Beyond Liver
Thomas J. Vogl
2. Emerging Thermal Ablation Applications
John McGahan
3. Emerging Cryo-ablation Applications
Peter Littrup
4. Emerging IMRT Applications – Ross Abrams
5. HIFU Beyond Fibroids – David Gianfelice
6. Irreversible Electroporation: Early Tumor Data
Stephen Kee
2:30 pm - 3:30 pm   Multimodality Session XIV
Co-Chairs: John McGahan & Ross Abrams

A31. Irreversible Electroporation (IE): A Novel Non-thermal Tumor Ablation Technique Resulting in Apoptotic Cell Death
E. W. Lee, S. T. Kee, C. T. Loh, V. E. Prieto, J. D. Grant - UCLA Medical Center, Los Angeles, CA.

A32. Management of Painful Acetabular Metastases by Combined Radiofrequency Ablation and Osteoplasty
S. S. KULKARNI, A. V. KULKARNI, A. R. BHALEKAR, D. ROY, M.H. Thakur - TATA MEMORIAL HOSPITAL, MUMBAI, INDIA.

A33. Cryotherapy for Benign and Cancerous Breast Tumors: US and CT-guidance
P. J. Littrup, L. Freeman-Gibb, B. Adam - Karmanos Cancer Center, Detroit, MI.

A34. Prognostic Impact of Dose and Selection in Thoracic Stereotatic Radiotherapy. Retrospective Analysis of 175 Treatments
G. Catalano1, F. Serafini1, G. Piperno1, R. Lazzari1, C. Garibaldi2, R. Cambria2, B. Tagaste2, P. Fossati1, M. Ciocca2, R. Orecchia3 - 1Radiotherapy Division, European Institute of Oncology, Milan, Italy, 2Medical Physic Unit, European Institute of Oncology, Milan, Italy, 3Chair of Radiotherapy University Milan, European Institute of Oncology, Milan, Italy.

A35. Rolse of Embolization prior to Cryoablation of Large Renal Tumors
D. A. Woodrum, T. D. Atwell, M. A. Farrell, M. R. Callstrom, J. C. Andrews, W. Charboneau - Mayo Clinic, Rochester, MN.

A36. Evaluation of Drug Loadable Porous Michrospheres for Doxorubicin Delivery Using a Vx-2 Tumor Model in Rabbit Liver
K. LEE, E. Liapi, M. Buijs, J. Vossen, V. Prieto Ventura, M. Vali, J. H. Geschwind - The Johns Hopkins Hospital, Baltimore, MD.

A37. An Apoptotic Enhancer Liposomal Paclitaxel Dramtically Increases RF Induced Coagulation in the R3230 Rat Tumor Model
S. N. Goldberg1, E. A. Abd El Hady1, E. M. Mostafa1, T. Levchenko2, V. Torchillin2, S. Signoretti3 - 1Beth Israel Deaconess Medical Center, Boston, MA, 2Northeastern University, Boston, MA, 3Brigham and Women's Hospital, Boston, MA.

A38. Controlled Radiofrequency Hyperthermia and Simultaneous Monitoring of its Effects in Sc-implanted 9L-glioma by In Vivo 1H, 23Na and 31P Magnetic Resonance Spectroscopy
J. R. James, Y. Gao, V. C. Soon, S. M. Topper, A. Babsky, N. Bansal - Department of Radiology, Indiana University School of Medicine, Indianapolis, IN.
3:30 pm - 4:00 pm   Refreshment Break
(Exhibit Hall)
4:00 pm - 5:30 pm   IO TREATMENT STRATEGIES Session V:
GU Tumors

Co-Chairs: Debra Gervais, Steve Raman, Stuart Silverman
(15 min. presentations)

1. Treatment Planning
Steve Solomon
2. Biopsy or No Biopsy Before Ablation
Stuart Silverman
3. Cryoablation versus RF Ablation for Renal Masses
Steve Raman
4. Size Matters: Upper and lower Limits of Renal Mass Ablation
Ronald Zagoria
5. Avoiding and Managing Complications of Renal Ablation
Peter Mueller
6. Imaging Follow Up after Renal Ablation: Basic Premises and Current Challenges
Debra Gervais
4:00 pm - 5:30 pm   IO TREATMENT STRATEGIES Session VI:
PRACTICE DEVELOPEMENT

Co-Chairs: Daniel Brown & Riad Salem
(10 min. presentations)

1. How to Set Up an IO Clinic
David Liu
2. Role of Physician Extenders
Kelvin Hong
3. Practice Building
Daniel Brown
4. Practice Management
Riad Salem
5. Managing an Inpatient Interventional Oncology Service
Tim Clark
6. What’s New in Reimbursement
Catherine Tuite
7. Q&A
5:30 pm   Adjourn


 

 
Program Archives

2007     Washington DC
2006     Italy
2005     London

 
Corporate Sponsors

Diamond Sponsors



Platinum Sponsors



Silver Sponsors



Bronze Sponsors

Philips Medical Systems



Co-Sponsors



Beverly Hills Sign